Serum levels of syndecan-1 in B-cell chronic lymphocytic leukemia: Correlation with the extent of angiogenesis and disease-progression risk in early disease

References

• Molica S, Vacca A, Ribatti D, Cuneo A, Cavazzini F, Levato D, et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood 2002; 100: 3344–3351
   PubMed Web of Science ®Google Scholar
• Molica S, Vacca A, Levato D, Merchionne F, Ribatti D. Angiogenesis in acute and chronic lymphocytic leukemia. Leukemia Res 2004; 28: 321–324
   PubMed Web of Science ®Google Scholar
• Chen H, Treweeke A T, West D C, Till K J, Cawley J C, Zuzel M, et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymhocytic leukemia cells. Blood 2000; 96: 3181–3187
   PubMed Web of Science ®Google Scholar
• Kay N E, Bone N D, Tschumper R C, Howell K H, Geyer S M, Dewold G W, et al. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 2002; 16: 911–919
   PubMed Web of Science ®Google Scholar
• Lee Y K, Strege A K, Bone N D, Shanafelt T D, Jelinek D F, Kay N E. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG) in B cell chronic lymphocytic leukaemia. Blood 2004; 104: 788–794
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F. Role of microenvironment in chronic lymphocytic leukaemia. Br J Haematol 2003; 123: 380–388
   PubMed Web of Science ®Google Scholar
• Carey D J. Syndecans: multifunctional cell-surface co-receptors. Biochem J 1997; 327: 1–16
   PubMed Web of Science ®Google Scholar
• Steinfeld R, Van Den B H, David G. Stimulation of fibroblastic growth factor receptor-1 occupancy and signalling by cell surface-associated syndecans and glypican. J Cell Biology 1996; 133: 405–416
   PubMed Web of Science ®Google Scholar
• Seidel C, Sundan A, Hjorth M, Turesson I, Dahl I M, Abildgaard N, et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 2000; 95: 388–395
   PubMed Web of Science ®Google Scholar
• Lowell R, Dunn J A, Begum G, Barth N J, Plant T, Moss P A, et al. Soluble syndecan-1 at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival. Br J Haematol 2005; 130: 542–548
   PubMed Web of Science ®Google Scholar
• Andersen N F, Standal T, Nielsen J L, Heickendorff L, Borset M, Sorensen F B, et al. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol 2005; 128: 210–217
   PubMed Web of Science ®Google Scholar
• Burger J A, Tsukada N, Burger M, Zvaifler N J, Dell'Aquila M, Kipps T J. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000; 96: 2655–2663
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennet J M, Grever M, Kay N, Keating M J, O'Brien S, et al. National Institute-sponsored working guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997
   PubMed Web of Science ®Google Scholar
• Binet J L, Auquier A, Dighiero G, Chastang C, Piquet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–206
   PubMed Web of Science ®Google Scholar
• Rozman C, Hernandez-Nieto L, Montserrat E, Brugues R. Prognostic significance of bone-marrow patterns in chronic lymphocytic leukaemia. Br J Haematol 1981; 47: 529–537
   PubMed Web of Science ®Google Scholar
• Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukemia: analysis of its prognostic significance. Br J Haematol 1968; 62: 567–575
   Web of Science ®Google Scholar
• Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503–508
   PubMed Web of Science ®Google Scholar
• Cuneo A, Bigoni R, Rigolin G M, Roberti M G, Dilani R, Bardi A, et al. Acquired deletion of the ataxia teleangectasia (ATM) locus in non-Hodgkin's lymphoma: correlation with clinicobiological features. J Clin Oncol 2000; 18: 2607–2614
   PubMed Web of Science ®Google Scholar
• Molica S. Progression and survival studies in early chronic lymphocytic leukemia. Blood 1991; 78: 895–899
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916
   PubMed Web of Science ®Google Scholar
• Kopper L, Sebestyen A. Syndecans and the lymphoid system. Leuk Lymphoma 2000; 38: 271–281
   PubMed Web of Science ®Google Scholar
• Sebestyen A, Kovalszky I, Mihalik R, Gallai M, Bocsi J, Laszlo E, et al. Expression of syndecan-1 in human B cell chronic lymphocytic leukaemia. Eur J Cancer 1997; 33: 2273–2277
   PubMed Web of Science ®Google Scholar
• Fayad L, Keating M J, Renben J M, O'Brien S, Lee B N, Lerner S, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 2001; 97: 256–263
   PubMed Web of Science ®Google Scholar
• Keating M, Lerner S, Kantarjan H, Freireich E, O'Brien S. The serum β2-microglobulin levels is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia. Blood 1995; 86: 6060
   Google Scholar
• Sarfati M, Chevret S, Chastang C, Biron G, Stryckmans P, Delespesse G, et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 1996; 88: 4259–4264
   PubMed Web of Science ®Google Scholar
• Hallek M, Langenmayer I, Nerl C, Knauf W, Dietzfelbinger H, Adorf D, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease-progression in early, non-smoldering chronic lymphocytic leukemia. Blood 1999 93: 1732–1737
   PubMed Web of Science ®Google Scholar
• Joensuu H, Anttonen A, Etikkson M, Makitaro R, Alfthan H, Kinnula V, et al. Soluble syndecan-1 and serum fibroblastic growth factor are new prognostic factors in lung cancer. Cancer Res 2002; 62: 5210–5217
   PubMed Web of Science ®Google Scholar
• Juuti A, Nordling S, Lundin J, Louhimo J, Haglund C. Syndecan-1 expression: a novel prognostic marker in pancreatic cancer. Oncology 2005; 68: 97–106
   PubMed Web of Science ®Google Scholar
• Leivonen M, Lundin J, Nordling S, Van Boguslawki K, Haglund S. Prognostic value of syndecan-1 expression in breast cancer. Oncology 2004; 67: 11–18
   Google Scholar
• Barretina J, Junca J, Llano A, Gutierrez A, Flores A, Blanco J, et al. CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of disease. Ann Haematol 2003; 82: 500–505
   PubMed Web of Science ®Google Scholar
• Hamblin T J, Davis Z, Gardiner A, Oscier D G, Stevenson F K. Unmutated IgV (H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854
   PubMed Web of Science ®Google Scholar
• Damle R N, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S L, et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847
   PubMed Web of Science ®Google Scholar
• Ibrahim S, Keating M J, Do K A, O'Brien S, Huh Y O, Jilani I, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001; 98: 181–186
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764–1775
   PubMed Web of Science ®Google Scholar
• Rassenti L Z, Huynh L, Toyl T L, Chen L, Keating M J, Gribben J G, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of desease-progression in chronic lymphocytic leukaemia. N Engl J Med 2004; 351: 893–901
   PubMed Web of Science ®Google Scholar